deferoxamine has been researched along with Delayed Puberty in 11 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications." | 5.12 | Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006) |
| "Delayed puberty was present in 18." | 2.72 | Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. ( De Sanctis, V; Fortini, M; Galati, MC; Gasser, T; Raiola, G; Roos, M, 2006) |
| "Body disproportion and severe degree of osteopenia (BMD SDSBA -2." | 1.31 | Persistence of delayed adrenarche in boys with thalassemia. ( De Martinis, F; De Terlizzi, F; Di Maio, S; Esposito, G; Filosa, A, 2001) |
| "Three patients had evidence of primary hypothyroidism." | 1.29 | Multiple hormone deficiencies in children with hemochromatosis. ( Cassorla, FG; Kamp, GA; Manasco, PK; Munson, PJ; Nienhuis, AW; Oerter, KE, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vogiatzi, MG | 1 |
| Autio, KA | 1 |
| Mait, JE | 1 |
| Schneider, R | 1 |
| Lesser, M | 1 |
| Giardina, PJ | 1 |
| De Sanctis, V | 3 |
| Roos, M | 1 |
| Gasser, T | 1 |
| Fortini, M | 1 |
| Raiola, G | 1 |
| Galati, MC | 1 |
| Wang, CH | 1 |
| Wu, KH | 1 |
| Tsai, FJ | 1 |
| Peng, CT | 1 |
| Tsai, CH | 1 |
| Pomarède, R | 1 |
| Girot, R | 1 |
| Constant, S | 1 |
| Rappaport, R | 1 |
| Gringras, P | 1 |
| Wonke, B | 3 |
| Old, J | 1 |
| Fitches, A | 1 |
| Valler, D | 1 |
| Kuan, AM | 1 |
| Hoffbrand, V | 1 |
| Borgna-Pignatti, C | 2 |
| Zurlo, MG | 1 |
| DeStefano, P | 1 |
| Boffa, C | 1 |
| DeSanctis, V | 1 |
| DiPalma, A | 1 |
| DiGregorio, L | 1 |
| Melevendi, C | 2 |
| Piga, A | 1 |
| Sabato, V | 1 |
| Oerter, KE | 1 |
| Kamp, GA | 1 |
| Munson, PJ | 1 |
| Nienhuis, AW | 1 |
| Cassorla, FG | 1 |
| Manasco, PK | 1 |
| Filosa, A | 1 |
| Di Maio, S | 1 |
| Esposito, G | 1 |
| De Martinis, F | 1 |
| De Terlizzi, F | 1 |
| Davies, SC | 1 |
| Vullo, C | 2 |
| Katz, M | 1 |
| Hoffbrand, VA | 1 |
| Di Palma, A | 1 |
| Bagni, B | 1 |
| De Stefano, P | 1 |
| Zonta, L | 1 |
| Naselli, A | 1 |
| Masera, G | 1 |
| Terzoli, S | 1 |
| Gabutti, V | 1 |
1 review available for deferoxamine and Delayed Puberty
| Article | Year |
|---|---|
The management of haemoglobinopathies.
Topics: Adolescent; Anemia, Sickle Cell; Bone Marrow Transplantation; Chelation Therapy; Child; Child, Presc | 1991 |
2 trials available for deferoxamine and Delayed Puberty
| Article | Year |
|---|---|
Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Body Height; Child; Child, Preschool; Deferoxamine; Female; Glu | 2006 |
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali | 2006 |
8 other studies available for deferoxamine and Delayed Puberty
| Article | Year |
|---|---|
Low bone mineral density in adolescents with beta-thalassemia.
Topics: Adolescent; Adult; Anthropometry; beta-Thalassemia; Blood Transfusion; Bone Density; Bone Diseases, | 2005 |
[Effect of hematologic treatment on the growth and puberty of children with thalassemia major].
Topics: Adolescent; Blood Transfusion; Body Height; Child; Combined Modality Therapy; Deferoxamine; Female; | 1984 |
Effect of alpha thalassaemia trait and enhanced gamma chain production on disease severity in beta thalassaemia major and intermedia.
Topics: Adolescent; Adult; alpha-Thalassemia; beta-Thalassemia; Blood Transfusion; Blotting, Southern; Defer | 1994 |
Outcome of thalassemia treated with conventional therapy.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Cardiovascular Diseases; Cause of Death; Chelation | 1993 |
Multiple hormone deficiencies in children with hemochromatosis.
Topics: Adolescent; Child; Deferoxamine; Endocrine System Diseases; Female; Follicle Stimulating Hormone; Go | 1993 |
Persistence of delayed adrenarche in boys with thalassemia.
Topics: Adolescent; Age Determination by Skeleton; Blood Transfusion; Body Height; Body Mass Index; Bone Den | 2001 |
Endocrine complications in thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Humans; Hypog | 1989 |
Growth and sexual maturation in thalassemia major.
Topics: Adolescent; Adult; Age Determination by Skeleton; Amenorrhea; Blood Transfusion; Body Height; Child; | 1985 |